Document:

RETENTION AGREEMENT (SCHWARTZ)

 Exhibit 10.5 
 RETENTION BONUS AGREEMENT FOR KEY EXECUTIVES 
 This agreement is entered into by and between Avici Systems Inc. (the
“Company”) and Esmeralda Swartz (“you”) effective as of February 28, 2006 (the “Effective Date”). 
 RETENTION BONUS 
 You will receive a retention bonus if (1) you remain actively employed full-time with the Company for the one-year
period immediately following the Effective Date (the “Retention Period”); (2) your employment is terminated without Cause; or (3) at the time of or following a Change of Control that occurs before the end of the Retention Period,
you are terminated from employment with the Company without Cause or resign for Good Reason. 
 The amount of the retention bonus will be six (6) months
of your base salary at the highest rate in effect during the Retention Period, less applicable taxes. The retention bonus will be paid in a lump sum within thirty (30) days following the end of the Retention Period or such earlier termination
date. 
 STOCK OPTIONS 
 Upon a Change of Control, at
least fifty percent (50%) of the unvested portion of each of your stock option awards granted under the Company’s 2000 Stock Option and Incentive Plan, as amended (the “Plan”), will immediately vest and become exercisable (by
crediting you for such purpose with additional service time, such that options will continue to vest following a Change of Control at the pre-existing number of shares per installment, but generally over one-half of the pre-existing remaining
vesting period). The remaining unvested portion of your options will continue to vest in accordance with the terms of the applicable agreement and the Plan following the Change of Control. 
 For example, if you have been awarded 120 options under the Plan that vest over four years at the rate of 2.5 options per month, after three years 90 of your options
will have vested and 30 will be unvested. Upon a Change of Control occurring at the end of year three, at least 15 of your 30 unvested options will immediately vest and become exercisable. Your remaining unvested options will continue to vest at the
rate of 2.5 per month. This will have the effect of reducing your remaining vesting period from one year to six months. 
 If at the time of or
following a Change of Control you are terminated without Cause or you resign for Good Reason, all of your unvested options under the Plan (including for clarity any options issued by an acquiror of the Company on assumption of or substitution for
your Company options) will immediately vest and become exercisable. 
 The above terms do not apply to any restricted stock grants, which continue to be
governed by the applicable agreement(s) and plan. 
  

 Page 1 of 3 

 DEFINITIONS; OTHER 
 A
termination for “Cause” as used herein means you are terminated by the Company due to (a) willful misconduct or violation of Company policy which causes material harm to the Company, (b) willful breach of an employment or
other agreement with the Company which causes material harm to the Company, or (c) being convicted of any felony. 
 A resignation for “Good
Reason” as used herein means you resign because, following or at the time of a Change of Control, (a) you are transferred to a different position or suffer a reduction in responsibility; (b) your compensation (excluding the
retention bonuses provided in this agreement) is decreased; (c) you are required to relocate more than fifty (50) miles from your work location immediately prior to the Change of Control; or (d) you are excluded from any material
compensatory or benefit plan or arrangement made available to similarly situated employees of the acquiring party. 
 “Change of Control” as
used herein means the closing of (a) the sale of the Company by merger, consolidation or purchase of outstanding capital stock in which the shareholders of the Company, as such, no longer own a majority of the outstanding equity securities of
the Company or its successor; (b) any sale of all or substantially all of the assets of the Company, other than in a spin-off or similar transaction; or (c) any other acquisition of the business of the Company, as determined by the Board.

 Assignment. This agreement will be binding on and inure to the benefit of the parties and the Company’s successors and assigns. 
 Confidentiality. You must keep this agreement confidential. The Company may publicly disclose the fact that you have been offered this agreement, the terms of
this agreement, and/or your receipt of a retention bonus under this agreement (the “Information”). If, prior to the Company’s public disclosure of any or all of the Information, either you disclose any or all of the Information to
anyone other than your spouse or financial advisor or your spouse or financial advisor discloses any or all of the Information, this agreement will become void and you agree to repay any payments already paid hereunder. 
 Employment at Will. This agreement is not an employment contract. Nothing in this agreement modifies your status as an employee at will or guarantees employment
for any length of time. 
 Entire Agreement; Modification; Governing Law. Except as otherwise provided herein, this agreement constitutes the only
agreement between you and the Company with respect to the subject matter hereof, superseding in all respects any and all prior oral or written agreements or understandings pertaining to the subject matter hereof. This agreement may be amended or
modified only in a writing signed by both you and the Company. Any dispute concerning this agreement will be governed by the internal laws of Massachusetts. 
  

 Page 2 of 3 

									
	AVICI SYSTEMS INC., by:	 		 	EMPLOYEE
					
	Print name:	 	William J. Leighton	 		 	Print name:	 	Esmeralda Swartz
	Signature:	 	/s/ William J. Leighton	 		 	Signature:	 	/s/ Esmeralda Swartz

  

 Page 2 of 3First Amendment to Collaboration Agreement

 Exhibit 10.1 
 [ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24B-2 of the Securities Exchange Act of 1934, as
amended. 
 First Amendment to the Collaboration Agreement 
 This first amendment (the “Amendment”) to the Collaboration Agreement dated December 22, 2006 (the “Agreement”)
between Exelixis, Inc. (“Exelixis”) and Genentech, Inc. (“Genentech”) is made and entered into by Exelixis and Genentech effective March 13, 2008 (the “Amendment Effective Date”). All
capitalized terms not expressly defined in this Amendment shall have the meaning assigned to them in the Agreement. 
 Whereas, Exelixis and Genentech
are parties to the Agreement; and 
 Whereas, Exelixis and Genentech wish to make certain amendments to the Agreement; 
 Now, therefore, in consideration of the foregoing premises the Parties do hereby agree to amend the Agreement, effective as of the Amendment Effective Date, as follows:

  

	1.	The following new Sections 1.75 through 1.77 are hereby added to the end of Article 1 of the Agreement: 

 1.75 “Development Plan Activities” means the activities directed toward achieving the primary, secondary, and
exploratory objectives listed under the heading “Development Plan Activities” in Exhibit D. 
 1.76
“Opt-In Date” means the date on which Exelixis receives Genentech’s written notification of its decision to exercise its Opt-In right pursuant to Section 3.4(b). 
 1.77 “Transfer Date” means the date on which Exelixis notifies Genentech of the first occurrence of [ * ] MTD has
been established consistent with the Development Plan Activities[ * ]. 
  

	2.	Section 2.1(d) of the Agreement is hereby amended and restated as follows: 

 “(d) Decision Making. The JSC shall make decisions unanimously, with each Party’s representatives collectively having one
(1) vote and at least one (1) representative from each Party present. In the event the JSC cannot reach an agreement regarding a decision within the JSC’s authority for a period of [ * ], then, except as otherwise set forth in this
Section 2.1(d) below, for the Collaboration: (i) Exelixis shall make the final determination in its sole discretion if such decision is regarding the [ * ] of Collaboration Compound(s) prior to [ * ], provided that Genentech shall make the
final determination in its sole discretion if such decision is regarding whether Exelixis [ * ] with respect to [ * ]; 

  

 [ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed
separately with the Securities and Exchange Commission pursuant to Rule 24B-2 of the Securities Exchange Act of 1934, as amended. 
 1.

 
and (ii) Genentech shall make the final determination in its sole discretion if such decision is regarding the [ * ] of Licensed Product(s) [ * ]
(although notwithstanding Genentech’s sole discretion under this Section, Genentech continues to be subject to [ * ]). Notwithstanding the foregoing, [ * ], Exelixis shall have final decision making authority for all matters relating to:
(x) [ * ]; and (y) [ * ]. [ * ], Genentech will have final decision making authority for all matters related to the [ * ]. When either Party makes final determinations under this Section, that final determination shall be consistent with
the terms of this Agreement. Disputes regarding matters not within the responsibilities of the JSC shall be resolved pursuant to Section 15.3.” 
  

	3.	Section 2.2(d) of the Agreement is hereby amended by replacing the phrase [ * ] with [ * ], and by replacing the phrase [ * ] with [ * ]. 

  

	4.	Section 3.1 of the Agreement is hereby amended and restated as follows: 

 “3.1 DC, TCP and Development Plan Activities. The Parties have agreed on the DC and TCP, which are attached as Exhibit
B and Exhibit C to this Agreement, respectively. The Parties have also agreed on the Development Plan Activities described in Exhibit D to this Agreement. The DC, TCP and Development Plan Activities may be amended only by the
Parties’ mutual written agreement. The Parties agree that the Existing Compound meets the DC and TCP. For other Collaboration Compounds, the JSC shall determine whether such Collaboration Compound has met the DC or TCP based on meeting all of
the objective criteria set forth in Exhibit B or Exhibit C, respectively.” 
  

	5.	Section 3.2(a) of the Agreement is hereby amended and restated as follows: 

 “(a) Development by Exelixis for Existing Compound. Exelixis shall, [ * ], use Diligent Efforts to conduct the Development
Plan Activities, including the Initial Phase I Trial, as set forth on Exhibit D, as amended, [ * ]. Except as expressly set forth in the Agreement, as amended, including, without limitation, in Section 3.5(c), 4.1(a), and 4.1(b), [ * ],
Exelixis [ * ] with respect to the Existing Compound, [ * ] pursuant to the terms of the Agreement.” 
  

	6.	The second sentence of Section 3.2(d) of the Agreement is hereby amended by: (1) replacing the phrase [ * ] with the phrase [ * ] and (2) replacing the phrase [ * ]
with the phrase [ * ]. 

  

	7.	Section 3.2(d) of the Agreement is amended by adding the following to the end of such section: 

 “[ * ], Exelixis will provide Genentech with [ * ] updates, including, without limitation, copies of the data generated by Exelixis pursuant to
Section 3.2(a) (as amended), on the Initial Phase I Trial and other information and data generated in connection with the Development Plan Activities. In addition, [ * ], Genentech’s representatives on the JPT, or, in place of such
representatives, an equivalent 

  

 [ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed
separately with the Securities and Exchange Commission pursuant to Rule 24B-2 of the Securities Exchange Act of 1934, as amended. 
 2.

 
number of Genentech’s designees, [ * ]: (i) [ * ]; and (ii) [ * ]. [ * ], if Genentech has [ * ] with: (1) [ * ]; or (2) [ * ], then
Exelixis’ representatives on the JPT, or, in place of such representatives, an equivalent number of Exelixis’ designees, may [ * ].” 
  

	8.	Section 3.2(f) of the Agreement is hereby amended and restated as follows: 

 “(f) Regulatory. Exelixis shall file and own all INDs for Collaboration Compounds that are the subjects of clinical trials to be carried out by Exelixis under this Agreement, subject to
Section 3.5(b), and shall be responsible for the filing of any additional necessary regulatory documents in the Profit-Share Territory for such Collaboration Compounds during the period [ * ] for those Collaboration Compounds. If Genentech
exercises its Opt-In right pursuant to Section 3.4 then Exelixis shall [ * ], and [ * ] for, any additional regulatory documents or filings, including any NDAs, with respect to any Licensed Product.” 
  

	9.	Section 3.4(a) of the Agreement is hereby amended and restated as follows: 

 “(a) Performance of Development Plan Activities.” Exelixis shall use Diligent Efforts in performance of the Development Plan Activities set forth on Exhibit D, including [ * ]. Exelixis will
notify Genentech promptly after [ * ] MTD for the Existing Compound is established consistent with the Development Plan Activities[ * ].” 
  

	10.	Section 3.4(b)(i) of the Agreement is hereby amended and restated as follows: 

 “(i) Genentech shall notify Exelixis in writing of its decision as to whether it will exercise its right to obtain a license for the development and commercialization of Licensed Product(s) containing any
Collaboration Compound (“Opt-In”) by [ * ] (the “Initial Opt-In Expiration Date”).” 
  

	11.	Section 3.4(b)(ii) of the Agreement is hereby amended and restated in its entirety as follows: “If, as of the Initial Opt-In Expiration Date, Genentech notifies Exelixis
in writing of its decision to exercise its Opt-In right with respect to such Existing Compound, then: (A) Genentech shall obtain a license, pursuant to Section 7.1, to develop and commercialize such Existing Compound and any other
Collaboration Compounds; and (B) all [ * ] Existing Compound will [ * ], but will [ * ]; provided, however, that Exelixis shall [ * ], under this Agreement. The Parties shall conduct further development activities and commercialization
activities with respect to such Collaboration Compounds and the associated Licensed Products pursuant to this Agreement, with Genentech being the Party responsible for the further clinical development (after the Transfer Date) of all Collaboration
Compound(s) and the commercialization of any Licensed Product(s) containing such Collaboration Compound(s). 

  

 [ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed
separately with the Securities and Exchange Commission pursuant to Rule 24B-2 of the Securities Exchange Act of 1934, as amended. 
 3.

	12.	Section 3.4(b)(iv) is hereby added to the Agreement to read as follows: 

 “(iv) If Genentech exercises its Opt-In right pursuant to Section, 3.4(b)(ii) and subsequently [ * ], to either (1) [ * ], or
(2) [ * ], then [ * ], the [ * ] under this Agreement regarding [ * ], but will [ * ], and the [ * ]. Thereafter Genentech shall use reasonable efforts [ * ], and the Parties shall [ * ]. If Genentech [ * ].” 
  

	13.	Section 3.5(a) of the Agreement is hereby amended and restated in its entirety as follows: 

 “(a) Effect of Opt-In; Protocol Amendment; Creation of Development Plan. Promptly after Exelixis receives Genentech’s
notice of its decision to Opt-In pursuant to Section 3.4, Exelixis shall provide Genentech with a copy of the protocol for the Initial Phase I Trial. Should Genentech want to amend this protocol, Genentech will provide Exelixis with the terms
of such amendment for review (the “Protocol Amendment”). The Parties understand and agree that any Protocol Amendment shall not [ * ]. Exelixis will provide, and Genentech will reasonably consider, any comments to the Protocol
Amendment within [ * ] of receipt thereof. Provided the Parties mutually agree on such Protocol Amendment, such agreement not to be unreasonably withheld by either Party, Exelixis will file such amendment for Regulatory Approval. [ * ], each Party
will use Diligent Efforts to transfer the conduct of the Initial Phase I Clinical Trial to Genentech so as to minimize any disruptions thereto. Thereafter, Genentech shall provide to Exelixis, through the JPT or JSC, a plan for the further
development of that Collaboration Compound and the associated Licensed Product which shall be incorporated herein by reference (the “Development Plan”). Genentech has final decision-making authority regarding any Development Plan;
the Development Plan shall reflect Genentech’s responsibility for the further clinical development (after the Transfer Date) of Collaboration Compound(s) in the Profit-Share Territory. Genentech may amend or update the Development Plan [ * ],
and shall provide such updated Development Plan to [ * ] at scheduled meetings of the JSC, but no more frequently than annually. The Development Plan is [ * ].” 
  

	14.	Section 3.5(c) of the Agreement is amended and restated to read in its entirety as follows: 

 “(c) Technical Assistance and Transfer. Exelixis shall transfer to Genentech the Information and documents described in subsections
(i) -(iii) below; provided, however, that except for those documents expressly set forth on Exhibit D-1, Exelixis shall not have any obligation to transfer or provide copies of any Information or documents pursuant to subsections
(i) and (ii) below that are [ * ] (e.g., [ * ]). 
 (i) Within [ * ], Exelixis shall, [ * ], transfer (or provide copies of,
as applicable) to Genentech (or a Third Party designated by Genentech) the Information associated with [ * ], the Parties will meet and discuss in good faith the technical assistance from Exelixis reasonably required for Genentech to [ * ], and the
commercially reasonable terms under which such technical assistance would be provided. 
  

 [ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed
separately with the Securities and Exchange Commission pursuant to Rule 24B-2 of the Securities Exchange Act of 1934, as amended. 
 4.

 (ii) Within [ * ], Exelixis shall, [ * ], disclose (and provide copies, as applicable) to
Genentech the “Priority” documents identified on Exhibit D-1. Within [ * ], Exelixis shall, [ * ], disclose (and provide copies, as applicable) to Genentech the “Other” documents identified on Exhibit D-1. In addition, within [ *
], Exelixis shall, [ * ] disclose (and provide copies, as applicable) to Genentech any other Information, including [ * ]. 
 (iii) [ *
], Exelixis shall transfer to Genentech: (1) [ * ], with respect to Collaboration Compounds, [ * ]; (2) [ * ] with respect to any Collaboration Compound; (3) [ * ]; and (4) [ * ], all [ * ] such Collaboration Compounds.”

  

	15.	Section 3.5(d) is amended and restated to read in its entirely as follows: 

 “(d) Development Costs. If Genentech exercises its Opt-In rights under Section 3.4(b) or Section 3.4(c); then[ * ]
Genentech shall bear one hundred percent (100%) of the Development Costs with respect to a Collaboration Compound and with respect to the associated Licensed Product incurred after the Transfer Date.” 
  

	16.	Section 4.1(a) of the Agreement is hereby amended and restated as follows: 

 “(a) Exelixis shall be the Party responsible, [ * ], for the Manufacture of Collaboration Compound(s) to supply the Development Activities [ * ] or pursuant to an Exelixis Work Plan, either by itself or through
one or more Third Parties (subject to Section [ * ]). Notwithstanding anything to the contrary in the Agreement, if [ * ], then Exelixis will be responsible, at [ * ]. In addition, within [ * ], at [ * ], Exelixis shall provide Genentech with [ * ]
in accordance with the terms of this Agreement.” 
  

	17.	Section 4.1(b) of the Agreement is hereby amended and restated as follows: 

 “(b) Except as otherwise agreed by the Parties, including as may be agreed pursuant to Section 3.5(c)(i), following the Opt-In Date Exelixis shall be relieved from any Manufacturing obligations for any
Collaboration Compound, except for: (1) the requirement to provide Collaboration Compound for the Initial Phase I Clinical Trial as set forth in Section 4.1(a) above; (2) the requirement to [ * ]; and (3) the obligation to
provide those quantities of Collaboration Compounds needed for Exelixis to perform Back-Up Work under an Exelixis Work Plan. Upon being relieved of its Manufacturing obligations, Exelixis shall, [ * ], use Diligent Efforts to transfer the
Manufacturing-related activities for those Collaboration Compounds for which it no longer has Manufacturing obligations to Genentech, pursuant to a mutually agreeable transfer plan. In addition to the transfer of documents and Information as set
forth under Section 3.5(c), such transfer shall include [ * ]. Where Genentech has taken over the responsibility for the 

  

 [ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed
separately with the Securities and Exchange Commission pursuant to Rule 24B-2 of the Securities Exchange Act of 1934, as amended. 
 5.

 
Manufacture of any Collaboration Compound(s) and related Licensed Product(s), Genentech may carry out such responsibilities either by itself or through one
or more Third Parties. Other than costs pursuant to carrying out the Manufacturing-related activities under the technological transfer consistent with Section 3.5(c) (which costs are borne by [ * ] pursuant to Section 3.5(c)), Fully
Burdened Manufacturing Costs (as defined in the Financial Appendix, and expressly including Third Party suppliers) incurred by Genentech (including in connection with engaging Third Party suppliers) for Collaboration Compound(s) and/or Licensed
Product(s) with be borne as follows: (i) if the product is for use in [ * ] (including [ * ]), such Fully Burdened Manufacturing Costs shall be deemed [ * ] and shall be borne [ * ]; (ii) if the product is for [ * ], such Fully Burdened
Manufacturing Costs shall be borne [ * ]; and (iii) if the product is for [ * ], such Fully Burdened Manufacturing Costs shall be [ * ] and [ * ]” 
  

	18.	Section 7.1(e) of the Agreement is hereby amended by inserting the following phrase at the end of subsection (i)(2): “, including without limitation the Initial Phase I
Trial (as set forth on Exhibit D)” 

  

	19.	Section 8.2(a) of the Agreement is hereby amended and restated in its entirety as follows: 

 “(a) if Genentech exercises its Opt-In right pursuant to Section 3.4(b), as amended, (i.e. with respect to an Existing Compound and all other
Collaboration Compounds), Genentech shall make the following payments to Exelixis: (i) $3,000,000 within [ * ] of the Opt-In Date, and (ii) $7,000,000 within [ * ] following the enrollment of the first human subject in the first Phase II
Clinical Trial for a Licensed Product containing the Existing Compound. For clarity, if Genentech [ * ]; provided, however, that Genentech shall [ * ] under this Agreement. Further, if Genentech [ * ], [ * ] Existing Compound.” 
  

	20.	The second sentence of Section 10.1(b) is hereby amended by inserting the phrase “; provided, however, that [ * ] shall have the right to use such Confidential Information
of [ * ] to [ * ], under this Agreement.” at the end of such sentence. 

  

	21.	Exhibit D is hereby amended and restated in its entirety, as described in the attached Appendix. 

  

	22.	Except as expressly and unambiguously stated herein, no other changes are made to the Agreement or Genentech’s rights following an Opt-In, and all other terms and conditions of
the Agreement shall remain in full force and effect. In the event of a conflict between the provisions hereof and the Agreement, the provisions of this Amendment shall control. The Agreement and this Amendment contains the entire understanding
between the Parties hereto with respect to the subject matter hereof and supersedes and terminates all prior agreements, understandings and arrangements between the Parties, whether written or oral with respect to such subject matter.

 Signature page follows. 
  

 [ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed
separately with the Securities and Exchange Commission pursuant to Rule 24B-2 of the Securities Exchange Act of 1934, as amended. 
 6.

 Accepted and Agreed: 

			
	
	GENENTECH, INC. By:
		
	By:	 	/s/ Ashraf Hanna
	Title:	 	VP Alliance Management
	Date:	 	March 13, 2008
	
	EXELIXIS, INC.
		
	By:	 	/s/ George A. Scangos, PhD
	Title:	 	President & CEO
	Date:	 	March 13, 2008

  

 [ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed
separately with the Securities and Exchange Commission pursuant to Rule 24B-2 of the Securities Exchange Act of 1934, as amended. 
 7.

 Appendix 
 Exhibit D 
 [ * ] 
  

 [ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed
separately with the Securities and Exchange Commission pursuant to Rule 24B-2 of the Securities Exchange Act of 1934, as amended. 
 8.

 Appendix 
 Exhibit D-1 
 Documents to be provided to Genentech by Exelixis [ * ] following a Genentech Opt-In:

 [ * ] 
  

 [ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed
separately with the Securities and Exchange Commission pursuant to Rule 24B-2 of the Securities Exchange Act of 1934, as amended. 
 9.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00141-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00141-of-00352.parquet"}]]